CancerDrs

Cervical Cancer clinical trials in District of Columbia

14 actively recruiting cervical cancer trials at 1 site across District of Columbia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in District of Columbia:
  • Research Site — Washington D.C., District of Columbia
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in District of Columbia:
  • The George Washington University — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in District of Columbia:
  • Avenzo Therapeutics Recruiting Site — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in District of Columbia:
  • The George Washington University Cancer Center (site 212) — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research s…

Sponsor: Massachusetts General Hospital
NCT ID: NCT05668962
Sites in District of Columbia:
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-d…

Sponsor: IDEAYA Biosciences
NCT ID: NCT07277413
Sites in District of Columbia:
  • Johns Hopkins Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Industry

Study of XB010 in Subjects With Solid Tumors

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumo…

Sponsor: Exelixis
NCT ID: NCT06545331
Sites in District of Columbia:
  • Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to estab…

Sponsor: Immunolight, LLC
NCT ID: NCT04389281
Sites in District of Columbia:
  • Sibley Hospital - Johns Hopkins University — Washington D.C., District of Columbia
Recruiting NIH

Biospecimen Procurement for Head and Neck Disorders

Background: Researchers want to learn more about head and neck disorders. Understanding these disorders could help them find better treatments. To do this, they are collecting tissue samples for research. Objective: To create a repository …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03429036
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • Johns Hopkins Hospital Sibley Memorial Hospital — Washington D.C., District of Columbia
  • George Washington University Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer

The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help par…

Sponsor: Georgetown University
NCT ID: NCT06980103
Sites in District of Columbia:
  • Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy

The current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy. Results with chemotherapy combined with full-dose radiation therapy leads to high …

Sponsor: Georgetown University
NCT ID: NCT06902623
Sites in District of Columbia:
  • Medstar Georgetown University Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women

The goal of this clinical trial is to test whether an interactive, video-based patient navigation program can improve cervical cancer screening among African American women who are currently overdue for screening. The main questions it aim…

Sponsor: ISA Associates, Inc.
NCT ID: NCT07011836
Sites in District of Columbia:
  • Family and Medical Counseling Service, Inc. — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients

The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategie…

Sponsor: Georgetown University
NCT ID: NCT06853925
Sites in District of Columbia:
  • Georgetown University — Washington D.C., District of Columbia

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19